MEK Inhibitor Active in NRAS-Mutated Melanoma

The MEK inhibitor MEK162 is the first agent to show some activity in patients with NRAS– and BRAF-mutated advanced melanoma, according to the conclusions of a phase II study, evaluating the drug’s safety and efficacy, published in Lancet Oncology. In addition, treatment with MEK162 resulted in the shrinkage of target brain metastases in two patients.

Research paper here: